Form 4: Amgen Director Charles Holley Acquires Shares

Amgen Director Charles M. Holley reported the acquisition of 265.4591 shares of common stock through a dividend reinvestment plan.

Summary

• Charles M. Holley, a Director at Amgen Inc., acquired 265.4591 shares of Amgen common stock.
• The transaction occurred on November 7, 2025, with a reported price of $0 per share.
• These shares are part of 1,393 Dividend Equivalents (DEs) granted under the Director Program, which are subject to a qualifying dividend reinvestment plan.
• Dividend Equivalents are credited on vested but deferred Restricted Stock Units (RSUs) and are paid out in shares of the Company's common stock on a one-to-one basis, with a cash payment for any remaining fractional share amount.
• Following this transaction, Mr. Holley directly owns 11,834.085 shares and indirectly owns 1,260 shares through the Holley Family Trust.

Sentiment

Score: 7

Explanation: The acquisition of additional shares by a director, even through a dividend reinvestment plan, generally indicates continued alignment of interests and confidence in the company's long-term prospects.

Positives

• A director acquiring additional shares, even through a dividend reinvestment plan, can signal continued confidence in the company's future performance.
• The transaction is part of a structured Director Program, indicating a consistent approach to director compensation and equity alignment with shareholder interests.

Negatives

• The acquisition price of $0 indicates these shares were granted as part of compensation (Dividend Equivalents), rather than an open market purchase with personal capital, which might be viewed differently by investors.

Related Party Transactions

• Indirect beneficial ownership of 1,260 shares of common stock is held through the Holley Family Trust.

Stakeholder Impact

• Shareholders: The director's increased stake, even if compensation-based, can be perceived as a positive signal of alignment and confidence in the company's future.

Key Dates

Recommendation

While the director's acquisition of shares through a dividend reinvestment plan is a positive signal of alignment and confidence, it is not an open market purchase with personal capital. This transaction alone does not provide sufficient new information to warrant a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate, maintaining current positions while monitoring further developments.

Keywords

Amgen, AMGN, Charles M. Holley, Director, Insider Transaction, Form 4, Stock Acquisition, Dividend Equivalents, Restricted Stock Units, Corporate Governance, Biotechnology, Pharmaceuticals